Cronos Group

Cronos Group (CRON) stock is currently trading at $3.35 per share on the NASDAQ exchange. This represents a daily decline of -0.89% ($0.0300) from the previous closing price of $3.38. Over the past 52 weeks, CRON has traded between a low of $2.28 and a high of $3.61, placing the current price at approximately -7% from its annual high. The stock has a market capitalization of $1.23B, making it one of the larger cannabis companies tracked by Cannabismarketcap. Cronos Group operates in the LP sector, classified under "MEDICINAL CHEMICALS & BOTANICAL PRODUCTS", serving the broader cannabis industry.

Cronos Group (CRON) has a current market capitalization of $1.23B, calculated by multiplying its 368.4M shares outstanding by the current stock price of $3.35. Market capitalization is a key measure of a company's total equity value as perceived by the public market, and it places Cronos Group among the large-cap cannabis companies tracked on Cannabismarketcap. Investors often use market cap alongside revenue and profitability metrics to assess relative valuation within the cannabis sector.

Cronos Group (CRON) currently reports a gross margin of 45.9%, which means the company retains 45.9 cents of every revenue dollar after direct costs of goods sold. On trailing twelve month revenue of $179.1M, this translates to an estimated gross profit of approximately $82.1M. Profitability is a critical factor in the cannabis industry, where many companies are still investing heavily in growth and regulatory compliance. Investors should review the full income statement, cash flow trends, and operating expense breakdown on Cannabismarketcap for a complete picture of Cronos Group's financial health.

Cronos Group (CRON) reports trailing twelve month (TTM) revenue of $179.1M, reflecting the total sales generated by the company over the most recent four quarters. Revenue has changed +37.46% year-over-year, indicating growth momentum relative to the prior period. The current price-to-sales ratio is 6.87x, which means investors are paying $6.87 for every $1 of annual revenue — a premium valuation in the context of the cannabis sector. Revenue is one of the most closely watched metrics for cannabis companies, as many are still scaling operations in a rapidly evolving regulatory environment. View the full income statement and quarterly revenue breakdown on Cannabismarketcap for detailed trend analysis.

Cronos Group currently employs approximately 610 people across its operations. As a licensed cannabis producer (LP) headquartered in Canada, its workforce supports activities spanning medicinal chemicals & botanical products and related business functions. Based on trailing twelve month revenue of $179.1M, this equates to approximately $293.6K in revenue per employee, which is a useful efficiency metric for comparing operational productivity across cannabis companies. Employee count is an important indicator of a company's operational scale and its capacity for growth in an industry that remains highly labor-intensive due to regulatory requirements.

Cronos Group trades under the ticker symbol CRON on the NASDAQ exchange, and the stock is denominated in US dollars (USD). Shares can typically be purchased through most standard brokerage accounts. The company has been publicly listed since 2016-06-03, giving it a track record in the public markets that investors can analyze for long-term trends. The stock sees average daily trading volume of approximately 535.7K shares, which is an important consideration for liquidity and the ability to enter or exit positions without significant price impact.

Cronos Group (CRON) has a gross margin of 45.9%, which represents the percentage of revenue the company retains after paying for the direct cost of goods sold. On trailing twelve month revenue of $179.1M, this translates to an estimated gross profit of approximately $82.1M. Gross margin is a critical profitability indicator in the cannabis industry, where companies face unique cost pressures from regulatory compliance, testing requirements, and the tax burden of IRC Section 280E (which prevents cannabis companies from deducting standard business expenses). A moderate gross margin like Cronos Group's suggests the company has pricing power and operational efficiency relative to peers.

Cronos Group (CRON) has traded between a 52-week low of $2.28 and a 52-week high of $3.61, with the current price of $3.35 sitting approximately -7% from the annual high. This range represents a spread of $1.33 (58% from low to high), which reflects the volatility the stock has experienced over the past year. The 52-week range is a commonly used technical indicator that helps investors understand whether a stock is trading near the top or bottom of its recent range, and it can inform decisions about entry and exit points. Cannabis stocks in general tend to exhibit higher volatility than broader market indices due to evolving regulations and market sentiment.

Cronos Group reports $467.0M in cash and equivalents; total debt is not reported in our data. Balance sheet strength is especially important in the cannabis industry, where companies often face limited access to traditional banking and capital markets. Investors should track these metrics over time on Cannabismarketcap to identify trends in cash consumption and debt management.

Cronos Group (CRON) currently has 368.4M shares outstanding, which when multiplied by the current stock price of $3.35 gives the company its market capitalization of $1.23B. Share count is important because all per-share metrics (earnings per share, book value per share, etc.) are directly impacted by changes in shares outstanding. Cannabis companies frequently issue new shares to raise capital, so monitoring dilution trends on Cannabismarketcap is recommended for long-term investors.